07:00 , Apr 9, 2012 |  BC Week In Review  |  Company News

Amgen, AstraZeneca deal

Amgen and AstraZeneca partnered to jointly develop and commercialize five of Amgen's human mAbs in its inflammation portfolio. The deal includes anti-IL17R mAb brodalumab (formerly AMG 827 ), which is slated to begin Phase III...
07:00 , Apr 9, 2012 |  BioCentury  |  Strategy

Divvying up skill sets

AstraZeneca plc 's deal for five clinical mAbs from Amgen Inc. 's inflammation and pulmonary portfolio puts the pharma close to its goal of getting 40% of its pipeline from external sources. For Amgen, last...
01:09 , Apr 3, 2012 |  BC Extra  |  Top Story

Amgen partners five mAbs with AZN

Amgen Inc. (NASDAQ:AMGN) and AstraZeneca plc (LSE:AZN; NYSE:AZN) partnered to jointly develop and commercialize five of Amgen's mAbs in its inflammation portfolio. The deal includes anti- IL17R mAb brodalumab (formerly AMG 827 ), which is...
08:00 , Nov 22, 2010 |  BioCentury  |  Regulation

Mild Was Enough

Leading up to last week's advisory committee meeting to discuss a BLA for lupus candidate Benlysta belimumab from Human Genome Sciences Inc. , the outcome hardly looked like a slam dunk. Based on a pair...